increasing incidence of cancer is driving the Liquid Biopsy Market
Technavio analyzes that the Liquid Biopsy Market is expected to grow at a CAGR of 25.2% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 3696.4 million.There are various factors that contribute to the growth of the market. The global Liquid Biopsy Market is experiencing significant growth due to the rising incidence of cancer worldwide. This non-invasive diagnostic approach offers numerous advantages over traditional methods, including early detection, real-time monitoring, and minimal invasiveness. Liquid biopsy enables the identification of cancer cells and biomarkers in various bodily fluids, providing valuable insights into the disease progression and response to treatment. This technology holds immense promise in the field of personalized medicine, offering tailored treatment plans based on individual patient profiles. The increasing burden of cancer and the need for more accurate and less invasive diagnostic tools are driving the growth of the liquid biopsy market.
The cancer applications segment represents a pivotal and essential part of the global liquid biopsy market. Liquid biopsy, utilizing advanced technologies such as Next-Generation Sequencing (NGS) and Polymerase Chain Reaction (PCR), has significantly transformed cancer diagnostics and monitoring. By detecting and analyzing cancer-related biomarkers, including circulating tumor DNA (ctDNA) and other tumor-specific molecules, from a patient's blood or other bodily fluids, liquid biopsy offers a minimally invasive alternative to traditional tissue biopsies. This non-invasive approach enhances patient comfort and reduces procedural risks. Furthermore, liquid biopsy plays a crucial role in personalized medicine and multi-cancer early detection (MCED) initiatives, providing diagnostic services for early and accurate identification of cancer, enabling more effective treatment strategies.
Know which region is leading the market growth by requesting a sample report
Liquid Biopsy Market Segmentation
As per our research findings, here are some of the key competitors that are leading the industry
Find out what is trending in the market by accessing the free PDF report
Liquid Biopsy is a revolutionary technology that offers non-invasive diagnosis, monitoring, and early detection of various diseases, primarily cancer. It enables real-time tumor monitoring and targeted cancer treatments through the analysis of biomarkers in bodily fluids. Applications include cancer diagnostics, non-invasive prenatal testing, transplantation medicine, and screening programs. Liquid biopsy assays, such as Multi-cancer early detection (MCED), are minimally invasive alternatives to conventional biopsy. This technology is transforming healthcare by providing early detection of breast, colorectal, ovarian cancer, and reducing cancer-related deaths. Cancer research also benefits from this non-invasive approach.
The Liquid Biopsy market is a significant segment of the global healthcare equipment industry, as identified by Technavio. This sector encompasses companies and innovations focused on real-time tumor monitoring, targeted cancer treatments, non-invasive prenatal testing, and transplantation medicine. As part of the broader healthcare equipment market, which covers R&D of capital equipment, instruments, implants, accessories, and consumables for disease diagnosis, monitoring, and treatment, the liquid biopsy market contributes to the industry's substantial revenue generation. Technavio calculates the market size based on the combined revenues of diagnostic equipment and devices manufacturers across various therapy areas. The healthcare equipment landscape consists of the following segments: Devices, which include advanced, differentiated, and clinically tested data-driven devices.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
